1009 related articles for article (PubMed ID: 8875929)
1. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
2. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
Popowicz GM; Czarna A; Holak TA
Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
[TBL] [Abstract][Full Text] [Related]
3. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
[TBL] [Abstract][Full Text] [Related]
4. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
5. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
7. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
11. Filling in the blanks in the p53 protein structure.
Pennisi E
Science; 1996 Nov; 274(5289):921-2. PubMed ID: 8966571
[No Abstract] [Full Text] [Related]
12. Structural details on mdm2-p53 interaction.
Chi SW; Lee SH; Kim DH; Ahn MJ; Kim JS; Woo JY; Torizawa T; Kainosho M; Han KH
J Biol Chem; 2005 Nov; 280(46):38795-802. PubMed ID: 16159876
[TBL] [Abstract][Full Text] [Related]
13. Binding induced folding in p53-MDM2 complex.
Chen HF; Luo R
J Am Chem Soc; 2007 Mar; 129(10):2930-7. PubMed ID: 17302414
[TBL] [Abstract][Full Text] [Related]
14. Repression of p53-mediated transcription by MDM2: a dual mechanism.
Thut CJ; Goodrich JA; Tjian R
Genes Dev; 1997 Aug; 11(15):1974-86. PubMed ID: 9271120
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
[TBL] [Abstract][Full Text] [Related]
16. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
18. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
19. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
20. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
Sakurai K; Chung HS; Kahne D
J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
